Aldeyra <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases Broad Immunology Pipeline Targeting Immune-Mediated Diseases in New R&D Presentation
Aldeyra Therapeutics Inc. presented an update on its research and development pipeline, highlighting progress across several immune-mediated disease programs. The company's RASP platform is advancing multiple candidates, including reproxalap for dry eye disease and allergic conjunctivitis, as well as ADX-248 and ADX-246 for atopic dermatitis, obesity/hypertriglyceridemia, and CNS/neuroinflammatory diseases. ADX-2191, which has received orphan drug designation from the U.S. FDA, is being developed for primary vitreoretinal lymphoma and retinitis pigmentosa. The investigational drug ADX-629 has demonstrated activity in Phase 2 clinical trials for autoimmune diseases such as psoriasis and atopic dermatitis, as well as hepatic inflammation and chronic cough. Statistically significant changes in lipid profiles were observed in multiple clinical trials with ADX-629. As of September 30, 2025, Aldeyra reported $75.3 million in cash, cash equivalents, and marketable securities, which it believes will fund operations into the second half of 2027. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.